文献速递流行病学与生物统计真实世界研究与卫生经济

伤寒结合疫苗不同接种方案的多模型比较:影响与成本效果

Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: A multi-model comparison.
PubMed 文献 · PLoS Med · 2026-10-13

世界卫生组织委托多模型比较,评估不同伤寒结合疫苗(TCV)接种方案在中等、高和极高发病率地区的健康与经济影响。四种动态模型拟合年龄别发病率数据,分析常规接种年龄、加强针和补种活动在免疫衰减快慢情景下的成本效果,发现9月龄常规接种加15岁补种和5岁加强针影响最大,中位减少40%-68%病例,但最优策略取决于发病率、病死率和免疫衰减速度。

要点

  • 9月龄常规接种+15岁补种+5岁加强针在10年内中位减少40%-68%病例。
  • 补种活动使TCV在中等发病率高成本高病死率、高发病率低成本低病死率情景下具成本效果。
  • 免疫衰减快时最优策略为延迟至2或5岁接种,取决于发病高峰年龄。

核心结论

  • 不同TCV接种方案的影响与成本效果预测对参数和模型结构不确定性较稳健,但最优策略取决于伤寒发病率、病死率和疫苗保护衰减速度。

研究设计与样本

  • 比较两种基于个体的模型和两种房室动态模型,均拟合中等、高和极高发病率地区的年龄别发病率数据。

主要发现

  • 10年时间范围内,9月龄常规接种加15岁补种和5岁加强针在中、高、极高发病率地区中位减少40%-68%病例。
  • 在中发病率地区,当疾病成本和病死率较高时,TCV引入加补种在支付意愿阈值高于每避免一个伤残调整生命年(DALY)1250美元时具成本效果。
  • 在高发病率地区,当成本和病死率较低时,相同策略在相同支付意愿阈值以上具成本效果。
  • 在极高发病率地区,9月龄或2岁接种可节省成本,5岁加强针在多数支付意愿值下具成本效果。

关键数值与推荐

  • 成本效果阈值:支付意愿高于每避免一个DALY 1250美元。
  • 免疫衰减快时,最优接种年龄为2岁或5岁,取决于发病高峰年龄。

临床怎么用

  • 在极高发病率地区可优先考虑9月龄或2岁接种,并评估5岁加强针。
  • 在中、高发病率地区引入TCV时应结合当地疾病成本、病死率和支付意愿阈值决定是否补种。
  • 免疫衰减速度影响接种年龄选择,需监测当地发病高峰年龄以优化策略。

局限性

  • 研究受限于间接疫苗保护的数据可得性及分析中所作的简化假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given emerging evidence on the waning of immunity from typhoid conjugate vaccines (TCV), the World Health Organization (WHO) commissioned a multi-model comparison to determine the optimal schedule in terms of health and economic impact to inform updated recommendations for TCV use across different settings. METHODS AND FINDINGS: To identify optimal vaccination strategies across different incidence settings and vaccine waning assumptions, we compared two agent-based and two compartmental dynamic models of typhoid transmission. All models were fitted to harmonized age-specific incidence data from medium, high, and very high incidence settings. We assessed different TCV schedules under slow- and fast-waning scenarios to evaluate the best age for routine vaccination and the potential need for booster doses and catch-up campaigns. We evaluated the public health and economic impact predicted for each model and scenario using the net-monetary-benefit framework to determine cost-effectiveness under two representative scenarios for the health outcomes and costs of vaccination and treatment. Over a 10-year time horizon, routine vaccination at 9 months with a catch-up campaign to 15 years and a booster dose at 5 years was predicted to have the greatest impact, reducing cases by a median of 40%-68% across the incidence settings. Across all four models, TCV introduction with a catch-up campaign was cost-effective above willingness-to-pay (WTP) thresholds of $1,250 per disability-adjusted life-year (DALY) averted in medium incidence settings when costs of illness and case fatality risk (CFR) are high and in high incidence settings when costs and CFR are low. The optimal strategy was to delay vaccination to 2 or 5 years of age if waning is fast, depending on the age of peak incidence. In very high incidence settings, TCV introduction at 9 months or 2 years of age was cost-saving, and adding a booster dose at 5 years was cost-effective at most WTP values across all scenarios. The study findings are limited by the data available to inform indirect vaccine protection and other simplifying assumptions made in this analysis. CONCLUSIONS: Model predictions for the impact and cost-effectiveness of different TCV schedules were fairly robust to uncertainty in parameter values and model structure, but the optimal strategy depends on the typhoid incidence rate, CFR, and waning rate of vaccine protection.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Wenger CGC, Grantz KH, Menkir TF, et al. Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: A multi-model comparison. PLoS Med. 2026. PMID: 42868196. doi:10.1371/journal.pmed.1005280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。